exocrine pancreatic insufficiency

Also found in: Dictionary, Acronyms, Wikipedia.
Related to exocrine pancreatic insufficiency: Chronic pancreatitis, Shwachman-Diamond syndrome

ex·o·crine pan·cre·at·ic in·suf·fi·cien·cy

lack of exocrine secretions of pancreas, due to destruction of acini, usually by chronic pancreatitis; lack of digestive enzymes from pancreas results in diarrhea, usually fatty (steatorrhea).


pertaining to the pancreas. See also pancreatitis, diabetes mellitus, cystic pancreatic duct.

pancreatic abscess
occurs as a complication of acute pancreatitis or subsequent to pancreatic surgery due to bacterial contamination but is most common as an extension from a leaking gastric ulcer.
pancreatic acinar atrophy
the islets of Langerhans remain normal but acinar tissue atrophies and exocrine function is compromised. Seen most commonly in large breeds of dogs, particularly German shepherd dogs. Clinical signs are related to the exocrine pancreatic insufficiency (see below).
acute pancreatic necrosis
see acute hemorrhagic pancreatitis.
alpha cells cells in the islet of Langerhans which secrete glucagon.
pancreatic anomaly
includes acinar hypoplasia and congenital Islet of langerhans aplasia.
beta cells comprise the majority of pancreatic islet cell population; secrete insulin.
pancreatic bladder
a diverticulum in the pancreatic duct like a gallbladder in the bile duct. Seen in some cats.
pancreatic C-cells
cells in the islet of Langerhans with no known function.
pancreatic calculus
small concretions, 4 to 5 mm diameter, in the pancreatic ducts, caused by chronic inflammation. Seen, usually in large numbers, in cattle.
pancreatic cysts
anomalous obstructions of ducts, often associated with similar cysts in kidneys and bile ducts.
pancreatic delta cells
cells in the islet of Langerhans; known to secrete somatostatin, and vasoactive intestinal peptide.
pancreatic duct
one of the two excretory ducts of the pancreas. Depending on the species, it may unite with the common bile duct before entering the duodenum at the major duodenal papilla. Absent from the pig and ox which only have an accessory pancreatic duct (developed from the dorsal primordium) which opens on the minor duodenal papilla. See also bile duct.
pancreatic duct obstruction
congenitally by agenesis of the duct, by pancreatic lithiasis or inflammation; causes initial distention followed by atrophy of acinar tissue.
pancreatic ectopic tissue
small masses of pancreatic exocrine or endocrine tissue found occasionally in the wall of the stomach or intestines and in the gallbladder; presumed to be functional.
pancreatic enzymes
the exocrine secretion into the intestine includes amylase, endo- and exopeptidases, and lipase. The endopeptidases include trypsin, chymotrypsin and elastase, the exopeptidases are the carboxypeptidases A and B.
exocrine pancreatic insufficiency
insufficient secretion of digestive enzymes, usually due to loss of acinar tissue from idiopathic atrophy or acute or chronic inflammation, causes maldigestion and malabsorption with diarrhea, steatorrhea and weight loss.
pancreatic fibrosis
a sequel to pancreatitis, pancreatic duct obstruction, zinc poisoning.
pancreatic fluke
pancreatic gastrinoma
a gastrin-producing tumor arising from the delta cells of the pancreatic islets that causes hypergastrinemia, hypersecretion of gastric acid and ulceration of the upper gastrointestinal tract. Occurs rarely in dogs. See also zollinger-ellison syndrome.
pancreatic hypertrophy
physiological response to diets high in protein and energy.
pancreatic islets
islets of cells scattered through the pancreas; contain alpha, beta, C and D cells.
pancreatic islet cell tumor
pancreatic lipase
enzyme released from the exocrine pancreas; catalyzes the hydrolysis of dietary lipids in the presence of bile salts. See also lipase.
pancreatic lithiasis
see pancreatic calculus (above).
pancreatic nodular hyperplasia
hard, pale elevations on the surface of the gland; involve only the exocrine tissue; common in old cats and dogs; cause unknown; no discernible effect on patient.
pancreatic polypeptide
secreted by the pancreas into the blood but has no apparent function.
pancreatic trypsin inhibitor
see trypsin inhibitor.
References in periodicals archive ?
Exocrine pancreatic insufficiency in a yellow-naped Amazon (Amazona ochrocephala) with pancreatic adenocarcinoma.
Prevalence and determinants of exocrine pancreatic insufficiency among older adults: results of a population-based study.
Exocrine pancreatic insufficiency is a frequent consequence of chronic or severe acute pancreatitis.
Rowland will lead commercialization efforts for liprotamase, the company's novel, oral, non-porcine pancreatic enzyme replacement therapy (PERT) designed to treat maldigestion, malabsorption and malnutrition as a result of exocrine pancreatic insufficiency associated with cystic fibrosis, chronic pancreatitis, pancreatic cancer, pancreatectomy and other pancreatic diseases.
Administration for the treatment of exocrine pancreatic insufficiency (EPI).
They can be used to measure gastric emptying rate of solids (1), detect fat malabsorption (2), and evaluate pancreatic lipase activity (3), exocrine pancreatic insufficiency (4), glucose adsorption and utilization (5), liver function control (6), and lactase deficiency (7) with appropriate [sup.
The DIGEST efficacy trial, which tested a one capsule per-meal dosing regimen, was designed to study fat absorption in cystic fibrosis patients with exocrine pancreatic insufficiency through the measurement of the coefficient of fat absorption (CFA).
Exocrine pancreatic insufficiency (EPI) is a deficiency of digestive enzymes normally produced by the pancreas that can result from a number of diseases, including cystic fibrosis, chronic pancreatitis, and pancreatic cancer -- EPI results in poor digestion and reduced absorption of nutrients which, if untreated, can lead to impaired growth in children, impaired immune response and shortened life expectancy -- Treatment with pancreatic replacement products replaces enzymes lost through this disease.
is a development-stage biopharmaceutical company committed to developing and delivering life-changing treatments for patients with exocrine pancreatic insufficiency due to cystic fibrosis.
Food and Drug Administration (FDA) for Zentase(TM) for the treatment of Exocrine Pancreatic Insufficiency (EPI).
The Food & Drug Administration (FDA) issued an approvable letter for Zentase, the company's lead drug candidate for the treatment of exocrine pancreatic insufficiency, in June.
Food and Drug Administration (FDA) recently approved CREON in a 36,000 lipase-unit dose to treat patients with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis, swelling of the pancreas that lasts a long time (chronic pancreatitis), removal of some or all of the pancreas (pancreatectomy), or other conditions.